Lege Artis Medicinae

[Diabetes mellitus and the liver]

BECHER Péter, PATAI Árpád, MÁJER Katalin

NOVEMBER 20, 2010

Lege Artis Medicinae - 2010;20(11)

[In the past years, the prevention of micro- and macrovascular complications has been the main target of diabetes treatment. Its unfavourable effects on the liver have been forgotten: the accelerated progression of the liver diseaeses and the increased risk of hepatocellular carcinoma. The multimetabolic syndrome leads to non-alcoholic fatty liver diseases (steatosis, steatohepatitis, cirrhosis). On he other hand some types of liver cirrhosis (for example the common alcoholic form) are worsening the insulin resistance, so they may due to a hepatogenous diabetes mellitus, that’s treatment is different and needs more regard, than type 2 diabetes.]

COMMENTS

0 comments

Related contents

Lege Artis Medicinae

[THE WORLDWIDE EPIDEMIC OF TYPE 2 DIABETES - CAUSES AND CONSEQUENCES]

JERMENDY György

[The prevalence of type 2 diabetes mellitus has recently dramatically increased worldwide. While many factors contribute to the startling data, including changes in the diagnostic criteria of glucose intolerance, increase of life expectancy, manifestation of diabetes at younger ages, and increased detection of unrecognized diabetes due to more efficient screening, the genuine, steep rise in the incidence of diabetes is explained by the increasing prevalence of obesity. Among the late complications of both diabetes and obesity, cardiovascular diseases are particularly important. Insulin resistance due to visceral obesity plays a central role in the pathomechanism of type 2 diabetes. In the prevention of both type 2 diabetes and obesity, non-pharmacological intervention such as life style changes should be considered first. Supplementary pharmacological treatment should target all cardiovascular risk factors.]

Lege Artis Medicinae

[RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY - A MULTICENTRIC STUDY]

SZALAY Ferenc, TELEGDY László, SZELI Dóra, CSÁK Tímea, FOLHOFFER Anikó, HORVÁTH Andrea, ABONYI Margit, SZABÓ Olga, RÉDEI Csaba, NEMESÁNSZKY Elemér

[INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3x400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.]

Lege Artis Medicinae

[Pregnancy and insulin resistance: theoretical and clinical issues]

BARANYI Éva, WINKLER Gábor

[During pregnancy, metabolic changes occur physiologically, which are enhanced by the presence of gestational or praegestational diabetes. The basis of these changes is the increasing insulin resistance throughout pregnancy, which in diabetics may result in hyperglycaemia with undesirable clinical consequences and complications. These complications can be prevented in diabetic pregnant women by maintaining the physiological metabolic state typical of healthy pregnant women. Thus the aim of the treatment is to achieve a normoglycaemic state throughout pregnancy. In most cases this is only possible by the use of insulin, along with appropriate dietary measures. Intensive insulin regimes are successfully used in the metabolic control of pregnant diabetic women, and the use of insulin analogues and insulin pump may also be considered.]

Lege Artis Medicinae

[Gestational diabetes mellitus and neuropathy: examining the relationship]

STELLA Péter, KERÉNYI ZSUZSA, NÁDASDI Ágnes, TABÁK Gy. Ádám, TAMÁS GYULA

[BACKGROUND - Little is known about the relationship between gestational diabetes and late diabetes complications. The relationship between these abnormalities was investigated in this study. PATIENTS, METHODS - Besides reclassification of their glucose tolerance, the prevalence and correlating factors of diabetic neuropathy were evaluated in 123 gestational diabetic (GDM) women controlled prior by our team during their pregnancies. 26 pregestational type 2 diabetic patients served as controls. Mean follow-up time was 7.2 years. Vibration perception threshold was measured to diagnose peripheral neuropathy, while cardiovascular autonomic neuropathy was evaluated using the battery of four cardiovascular reflex-tests. RESULTS - From 123 prior GDM women, 63 were characterized as having diabetes (52.9%), while 14 had impaired glucose tolerance (11.8%). Peripheral neuropathy was diagnosed in 23.6 %, parasympathetic neuropathy in 37.4 %, while sympathetic neuropathy was confirmed in 7.3 % of the patients evaluated during follow-up visit. Association between abnormal glucose tolerance and neuropathy was statistically significant only in the case of parasympathetic neuropathy (p=0.0001), and this relationship was independent from elevated BMI, microalbuminuria and the higher rate of hypertension observed in these women (p=0.006). Since the number of abnormal neuropathy tests were also higher than expected in women with normal glucose tolerance, we hypothetised a cross-sectional link between neuropathy and insulin resistance. An additional analysis comfirmed this association between insulin resistance and parasympathetic neuropathy independent of metabolic status of these patients (p=0.005). CONCLUSIONS - The importance of gestational diabetes, which is sometimes underestimated by many clinicians, was highlighted by our study since it projected a high frequency of parasympathetic cardiovascular neuropathy in these patients. This form of diabetes not only projects the development of late onset type 2 diabetes, but could also act as a predictor of late diabetes complications. According to our results diabetic parasympathetic neuropathy may be linked to type 2 diabetes/ insulin resistance syndrome, and could play a role in the excess cardiovascular mortality observed in these patients.]

Lege Artis Medicinae

[INSULIN RESISTANCE: FOCUS ON THE ADIPOSE TISSUE]

URICH Elemér

[Insulin resistance is defined as a state of subnormal biological response to normal quantity of insulin. This phenomenon was first described by Hinsworth and Kerr in 1939, however it has come to the centre of interest only in the last two decades. It is the central pathogenetic factor of type 2 diabetes and the more complex clinical entity of metabolic syndrome, consequently also referred to as insulin resistance syndrome. In the background of insulin resistance alterations of the adipose tissue can be observed which clinically means obesity in most of the cases, however, this issue cannot be simplified to obesity only as increase in adipose tissue growth may be beneficial in certain cases. Current article discusses the explanation of this paradox and the pathophysiologic link between adipose tissue and insulin resistance. It also reviews the therapeutic aspects of insulin resistance emphasizing the role of thiazolidinedione type drugs having recently joined the therapeutic palette.]